Last reviewed · How we verify
Pneumovax (PPSV23)
Pneumovax (PPSV23) is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria.
Pneumovax (PPSV23) is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria. Used for Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis), Prevention of pneumococcal otitis media and sinusitis.
At a glance
| Generic name | Pneumovax (PPSV23) |
|---|---|
| Also known as | 23-valent pneumococcal capsular polysaccharide vaccine, PPSV23, Pneumovax |
| Sponsor | University of Minnesota |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PPSV23 contains purified capsular polysaccharides from 23 different pneumococcal serotypes conjugated to a carrier protein. When administered, it triggers B-cell and T-cell mediated immune responses, leading to the production of opsonizing antibodies that enhance phagocytosis and complement-mediated killing of pneumococcal bacteria. This provides protection against invasive pneumococcal disease including pneumonia, bacteremia, and meningitis.
Approved indications
- Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis)
- Prevention of pneumococcal otitis media and sinusitis
Common side effects
- Injection site erythema or induration
- Myalgia or arthralgia
- Fever
- Headache
- Fatigue
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumovax (PPSV23) CI brief — competitive landscape report
- Pneumovax (PPSV23) updates RSS · CI watch RSS
- University of Minnesota portfolio CI